BACKGROUND: Cerebralcare Granule (CG) is a polyherbal Chinese medicine that has been shown to have neuroprotective effects in experimental models of @entity64 . We compared the efficacy and safety of CG with @entity117 in @entity1 with @entity64 . METHODS: For this open-label, controlled trial, we recruited @entity1 with angiographically confirmed @entity64 and US National Institutes of Health @entity64 Scale (NIHSS) scores of 4-22 within 2 weeks of symptom onset; recruitment was performed at 55 sites in China. @entity1 received CG or @entity117 . The primary efficacy end-point was neurological function. Analyses were done by intention to treat. @entity1 were measured for NIHSS, Montreal Cognitive Assessment, and Mini-Mental State Examination scores and Barthel index at baseline and at 4, 8, and 12 weeks after treatment. RESULTS: Between January 2013 and January 2014, we treated 1963 @entity1 with CG and 1288 @entity1 with @entity117 . Baseline NIHSS, Mini-Mental State Examination, and Montreal Cognitive Assessment scores were comparable between the two groups. @entity1 in the CG group had a greater improvement than the @entity117 group in terms of NIHSS (P < 0.01) and Barthel index at 4, 8, and 12 weeks. At 12 weeks, @entity1 in the CG group had a greater improvement than the @entity117 group in terms of Mini-Mental State Examination (P < 0.01) and Montreal Cognitive Assessment (P < 0.05). Adverse reactions were similar between the two groups. CONCLUSIONS: This large-scale, controlled trial indicated that CG may be a useful treatment in the management of post- @entity64 @entity1 .

Comparing Cerebralcare Granule and @entity117 for neurological dysfunction in XXXX in real-life practice.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'stroke', 'acute stroke', 'Stroke']
@entity64 :: (MESH:D020521,Disease) :: ['acute stroke']
